1. Accueil
  2. Publications internationales de l’Institut du Cancer de Montpellier

Publications internationales de l’Institut du Cancer de Montpellier

Une production scientifique de haut niveau

Les praticiens et chercheurs de l'ICM contribuent aux avancées en cancérologie comme en atteste le nombre de publications scientifiques. En 2023, 277 publications pour un score SIGAPS de 2847. 55% des publications proviennent de revues de rang A+, A ou B.

Publications 2023 de rang A+

  • Planchard, D ; Jänne, PA ; Cheng, Y ; Yang, JC ; Yanagitani, N ; Kim, SW & al. Inv:QUANTIN, X. Osimertinib with or without Chemotherapy in  EGFR-Mutated Advanced NSCLC. The New England Journal of Medicine, 2023, (389) : 1935-1948
  • Chu, Q ; Perrone, F ; Greillier, L ; Tu, W ; Piccirillo, MC ; Grosso, F; (…) QUANTIN, X & al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet, 2023 (402) : 2295-2306
  • Zhou, C ; Solomon, B ; Loong, HH ; Park, K ; Pérol, M ; Arriola, E & al. Inv: QUANTIN, X. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in  <i>RET</i> Fusion-Positive NSCLC. The New England Journal of Medicine, 2023, (389) : 1839-1850
  • Loriot, Y ; Matsubara, N ; Park, SH ; Huddart, RA ; Burgess, EF ; Houede, N & al. Inv: TOSI, D.  Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. The New England Journal of Medicine, 2023 (389) : 1961-1971
  • Hurvitz, SA ; Hegg, R ; Chung, WP ; Im, SA ; Jacot, W ; Ganju, V & al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, 2023 (401) : 105-117

Publications 2023 de rang A

  • David, T ; Mallavialle, A ; Faget, J ; Alcaraz, LB ; Lapierre, M ; du Roure, PD ; (…) JARLIER, M ; GUIU, S & al. Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer. British Journal of Pharmacology, 2023
  • Kabirian, R ; Franzoi, MA ; Havas, J ; Coutant, C ; Tredan, O ; Levy ; (…) C, ROUANET, P & al.  Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer. JAMA Network Open, 2023, (6) : e2343910
  • Garcia-Prada, CD ; Carmes, L ; Atis, S ; Parach, A ; Bertolet, A ; Jarlier, M  & al. ADA : CONSTANZO, J. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. Journal of Nuclear Medicine, 2023 (64) : 1956-1964
  • Thierry, AR ; Pisareva, E. A New Paradigm of the Origins of Circulating DNA in Patients with Cancer. Cancer Discovery, 2023 (13) : 2122-2124
  • Leman, R ; Muller, E ; Legros, A ; Goardon, N ; Chentli, I ; Atkinson, A & al. Inv: FABBRO, M. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer. Clinical Cancer Research, 2023 (29) : 4419-4429
  • Boige, V ; Blons, H ; François, E ; Ben Abdelghani, M ; Phelip, JM ; Le Brun-Ly, V ; (...) GOURGOU-BOURGADE, S & al. ADA:CASTAN, F. Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Network Open, 2023 (6) : e2333533
  • Drakaki, A ; Powles, T ; Bamias, A ; Martin-Liberal, J ; Shin, SJ ; Friedlander, T ; (...) TOSI, D & al. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clinical Cancer Research, 2023 (29) : 4373-4384
  • Kurtz, JE ; Pujade-Lauraine, E ; Oaknin, A ; Belin, L ; Leitner, K ; Cibula, D ; (...) D'HONDT, V & al. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. Journal of Clinical Oncology, 2023 (41) : 4768-4778
  • Niyoteka, S ; Seban, RD ; Rouhi, R ; Scarsbrook, A ; Genestie, C ; Classe, M ; (...) LEMANSKI, C & al. A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers. European Journal of Nuclear Medicine and Molecular Imaging, 2023 (50) : 4010-4023
  • Pouget, JP ; Chan, TA ; Galluzzi, L ; Constanzo, J. DA : CONSTANZO, J. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors. Trends Cancer, 2023 (9) : 968-981
  • Glaviano, A ; Foo, ASC ; Lam, HY ; Yap, KCH ; Jacot, W ; Jones, RH & al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer, 2023 (22) : 138
  • Primavesi, F ; Maglione, M ; Cipriani, F ; Denecke, T ; Oberkofler, CE ; Starlinger, P ; (...) POPESCU, O & al. E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy. British Journal of Surgery, 2023 (110) : 1331-1347
  • Thibaudin, M ; Fumet, JD ; Chibaudel, B ; Bennouna, J ; Borg, C ; Martin-Babau, J ; (...) MICHAUD, H-A & al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nature Medicine, 2023 (29) : 2087-2098
  • Huober, J ; Weder, P ; Ribi, K ; Thürlimann, B ; Thery, JC ; Li, Q ; (...) GUIU, S & al. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology, 2023 (9) : 1381-1389
  • Collard, MK ; Rullier, E ; Tuech, JJ ; Sabbagh, C ; Souadka, A ; Loriau, J ; (...) ROUANET, P & al. Is Delaying a Coloanal Anastomosis the Ideal Solution for Rectal Surgery?: Analysis of a Multicentric Cohort of 564 Patients From the GRECCAR. Annals of Surgery, 2023 (278) : 781-789
  • Kim, S ; Vendrely, V ; Saint, A ; André, T ; Vaflard, P ; Samalin, E & al. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study. Experimental Hematology & Oncology, 2023 (12) : 63
  • Faron, M ; Cheugoua-Zanetsie, M ; Tierney, J ; Thirion, P ; Nankivell, M ; Winter, K ; (...) YCHOU, M & al. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. Journal of Clinical Oncology, 2023 (41) : 4535-4547
  • Blay, JY ; Chevret, S ; Le Cesne, A ; Brahmi, M ; Penel, N ; Cousin, S ; (...) TOSI, D & al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncology, 2023 (24) : 892-902
  • Taibi, A ; Sgarbura, O ; Villeneuve, L ; Eveno, C ; Pocard, M ; Bakrin, N & al. Developing a core set of patient-reported outcomes and patient-reported experience measures for peritoneal surface malignancies (COMETE). British Journal of Surgery, 2023 (110) : 1087-1091
  • Taprogge, J ; Vergara-Gil, A ; Leek, F ; Abreu, C ; Vávrová, L ; Carnegie-Peake, L & al. ADA:BARDIES, M. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. European Journal of Nuclear Medicine and Molecular Imaging, 2023 (50) : 3225-3234
  • Gómez Ruiz, M ; Espin-Basany, E ; Spinelli, A ; Cagigas Fernández, C ; Bollo Rodriguez, J ; María Enriquez Navascués, J & al. Inv: ROUANET, P ; Inv: TAOUM, C. Early outcomes from the Minimally Invasive Right Colectomy Anastomosis study (MIRCAST). British Journal of Surgery, 2023 (110) : 1153-1160
  • Tarantino, P ; Viale, G ; Press, MF ; Hu, X ; Penault-Llorca, F ; Bardia, A ; (...) JACOT, W & al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Annals of Oncology, 2023 (34) : 645-659
  • Lequesne, J ; Joly, F ; Peron, J ; Ray-Coquard, I ; Hardy-Bessard, AC ; Selle, F ; (...) FABBRO, M & al. Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy. Journal of the National Comprehensive Cancer Network, 2023 (21) : 473-479.e4
  • Villemin, JP ; Bassaganyas, L ; Pourquier, D ; Boissière, F ; Cabello-Aguilar, S ; Crapez, E ; (...) TANOS, R & al. DA : COLINGE, J. Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR. Nucleic Acids Research, 2023 (51) : 4726-44
  • Hutchinson, KE ; Chen, JW ; Savage, HM ; Stout, TJ ; Schimmoller, F ; Cortés, J ; (...) JACOT, W & al. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers. Genome Medicine, 2023 (15) : 28
  • Adam, J ; Stang, NL ; Uguen, A ; Badoual, C ; Chenard, MP ; Lantuéjoul, S ; (...) MARAN-GONZALEZ, A & al. Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions. Modern Pathology, 2023 (36) : 100192
  • Alaoui, L ; Villar, J ; Leclere, R ; Le Gallou, S ; Relouzat, F ; Michaud, HA & al. Functional specialization of short-lived and long-lived macrophage subsets in human tonsils. Journal of Experimental Medicine, 2023 (220)
  • Borg, JP ; Colinge, J ; Ravel, P. Modular response analysis reformulated as a multilinear regression problem. Bioinformatics, 2023 (39)
  • Chi, KN ; Rathkopf, D ; Smith, MR ; Efstathiou, E ; Attard, G ; Olmos, D & al. Inv: TOSI, D. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2023 (41) : 3339-3351
  • Durand, C ; Magloire, L ; Cousson-Gélie, F ; Bord, A ; Saboni, L ; Zeghnoun, A & al. Efficacy of an appearance-based and a health-based sun protection intervention on summer vacationers'' behaviours, PRISME cluster randomized crossover trial, France. British Journal of Health Psychology, 2023 (28) : 724-739
  • Pilkington, M ; Nelson, G ; Cauley, C ; Holder, K ; Ljungqvist, O ; Molina, G & al. Inv: POPESCU, O. Development of an Enhanced Recovery After Surgery Surgical Safety Checklist Through a Modified Delphi Process. JAMA Network Open, 2023 (6) : e2248460
  • Conroy, T ; Castan, F ; Hammel, P. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply. JAMA Oncology, 2023 (9) : 436-437
  • Glasson, Y ; Chépeaux, LA ; Dumé, AS ; Lafont, V ; Faget, J ; Bonnefoy, N & al. ADA: BONNEFOY, N ; DA : MICHAUD, H-A. Single-cell high-dimensional imaging mass cytometry: one step beyond in oncology. Semin Immunopathol, 2023 (45) : 17-28
  • Taffoni, C ; Marines, J ; Chamma, H ; Guha, S ; Saccas, M ; Bouzid, A ; (...) DEL RIO, M & al. DNA damage repair kinase DNA-PK and cGAS synergize to induce cancer-related inflammation in&nbsp;glioblastoma. The EMBO Journal, 2023 (42) : e111961
  • Lista, S ; Vergallo, A ; Teipel, SJ ; Lemercier, P ; Giorgi, FS ; Gabelle, A & al. Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer''s disease: relevance for precision medicine in neurodegenerative diseases. Ageing Research Reviews, 2023 (84) : 101819
  • Cashin, PH ; Esquivel, J ; Larsen, SG ; Liauw, W ; Alzahrani, NA ; Morris, DL ; (...) POPESCU, O ; QUENET, F & al. Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched study. eClinicalMedicine, 2023 (55) : 101746
  • Gourlan, M ; Ricupero, S ; Carayol, M ; Cousson-Gélie, F. DA : COUSSON-GELIE, F. Efficacy of theory-based interventions aimed at reducing binge drinking in adolescents: A systematic review and meta-analysis of randomised controlled trials. Social Science & Medicine, 2023 (317) : 115571
  • Girardi, F ; Matz, M ; Stiller, C ; You, H ; Marcos Gragera, R ; Valkov, MY & al. Inv: TRETARRE, B.  Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro-Oncology, 2023 (25) : 580-592
  • Sinoquet, L ; Jacot, W ; Quantin, X ; Alix-Panabières, C. Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. Clinical Chemistry, 2023 (69) : 23-40
  • Palassin, P ; Faillie, JL ; Coustal, C ; Quantin, X ; Topart, D ; Roubille, F & al. Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys. Journal of Clinical Oncology, 2023 (41) : 1154-1156
  • Robert, M ; Chépeaux, LA ; Glasson, Y ; Dumé, AS ; Sannier, A ; Papo, T : (...) BONNEFOY, N & al. ADA : MICHAUD, H-A. Comprehensive analysis of cell lineages involved in giant cell arteritis pathogenesis using highly multiplexed imaging mass cytometry. Autoimmunity Reviews, 2023 (22) : 103216
  • Pisareva, E ; Badiou, S ; Mihalovičová, L ; Mirandola, A ; Pastor, B ; Kudriavtsev, A & al. DA : THIERRY, A. Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute&nbsp;phase COVID-19 patients. Journal of Medical Virology, 2023 (95) : e28209
  • Nardin, C ; Lesage, C ; Goubeau, E ; Aubriot-Lorton, MH ; Lacheretz-Szablewski, V ; Ortonne, N & al. Cutaneous vasculitis associated with mycosis fungoides. Journal of the European Academy of Dermatology and Venereology, 2023 (37) : e204-e206
  • Depypere, H ; Vergallo, A ; Lemercier, P ; Lista, S ; Benedet, A ; Ashton, N & al. Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer''s disease. Alzheimer's & Dementia Journal, 2023 (19) : 1320-1330
  • Girardi, F ; Di Carlo, V ; Stiller, C ; Gatta, G ; Woods, RR ; Visser, O & al. Inv : TRETARRE, B. Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). Neuro-Oncology, 2023 (25) : 593-606
  • Hindman, N ; Kang, S ; Fournier, L ; Lakhman, Y ; Nougaret, S ; Reinhold, C & al. MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement. Radiology, 2023 (306) : e211658
  • André, T ; Tougeron, D ; Piessen, G ; de la Fouchardière, C ; Louvet, C ; Adenis, A & al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology, 2023 (41) : 255-265
  • Moulin, F ; Bailhache, M ; Monnier, M ; Thierry, X ; Vandentorren, S ; Côté, SM & al. Longitudinal impact of psychosocial status on children''s mental health in the context of COVID-19 pandemic restrictions. European Child & Adolescent Psychiatry, 2023 (32) : 1073-1082
  • Hotton, J ; Lusque, A ; Leufflen, L ; Campone, M ; Levy, C ; Honart, JF ; (...) GUTOWSKI, M & al. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort. Annals of Surgery, 2023 (277) : e153-e161